As of May 16, 2018 Aemetis Inc (NASDAQ:AMTX) Shorts Declined By 25.77%

May 16, 2018 - By Alma Kearns

Aemetis, Inc. (NASDAQ:AMTX) Corporate Logo

Aemetis Inc (NASDAQ:AMTX) recorded a decrease of 25.77% in shares shorted. It was issued in May by FINRA the 258,400 shares shorted on AMTX. The down change of 25.77% from 348,100 shares was reported. Previous AMTX’s position will need 2 days to recover. It has 107,500 average volume. Aemetis Inc float short is 1.8%.

AMTX is touching $1.775 during the last trading session, after decreased 0.84%.Currently Aemetis, Inc. is uptrending after 78.07% change in last May 16, 2017. AMTX has also 11,585 shares volume. AMTX outperformed the S&P500 by 66.52%.

Aemetis, Inc. operates as an international renewable fuels and bio-chemicals firm in North America and India.The firm is valued at $35.90 million. It focuses on the production of advanced fuels and chemicals through the acquisition, development, and commercialization of technologies that replace traditional petroleum products by conversion of first-generation ethanol and biodiesel plants into advanced bio refineries.Last it reported negative earnings. The firm owns and operates a biodiesel plant in Kakinada, India; and an ethanol plant in Keyes, California.

A couple more Aemetis, Inc. (NASDAQ:AMTX) news were published by: which released on May 13, 2018 “Aemetis’ (AMTX) CEO Eric McAfee on Q1 2018 Results – Earnings Call Transcript”, also on May 03, 2018 published “Aemetis CEO to Present at the Disruptive Growth & Healthcare Conference on May 9th”, the next is “Upgraded Aemetis Plant in India Completes Biodiesel Production Using Lower Cost, High FFA Waste Feedstock” on April 25, 2018. has article titled “Aemetis to Review First Quarter Financial Results on May 10, 2018”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: